Skip to main content

ORIGINAL RESEARCH article

Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1529582
This article is part of the Research Topic New Insights into the Pathogenesis of Idiopathic Inflammatory Myopathy View all 4 articles

Ultrasensitive Interferons quantification reveals different cytokine profile secretion in inflammatory myopathies and can serve as biomarkers of activity in Dermatomyositis

Provisionally accepted
Loïs BOLKO Loïs BOLKO 1*Céline Anquetil Céline Anquetil 2,3Alba Llibre Alba Llibre 4Solène Maillard Solène Maillard 3Damien Amelin Damien Amelin 3Karim Dorgham Karim Dorgham 5Vincent BONDET Vincent BONDET 4Océane Landon-Cardinal Océane Landon-Cardinal 6Ségolène Toquet Ségolène Toquet 2,3Kuberaka Mariampillai Kuberaka Mariampillai 3Samuel Malatre Samuel Malatre 2Alexandrine Mahoudeau Alexandrine Mahoudeau 3Baptiste HERVIER Baptiste HERVIER 2Mathieu Rodero Mathieu Rodero 7Guy Gorochov Guy Gorochov 5Darragh Duffy Darragh Duffy 4Olivier Benveniste Olivier Benveniste 2,3Yves ALLENBACH Yves ALLENBACH 2,3
  • 1 Rheumatology, Christian Cabrol Hospital, Reims, France
  • 2 Département de médecine interne et d'immunologie clinique, Hôpitaux Universitaires Pitié Salpêtrière, Paris, France
  • 3 INSERM U974 Institut de Myologie, Paris, Île-de-France, France
  • 4 INSERM U1223 Physiopathologie du Système Immunitaire, Institut Pasteur, Paris, Île-de-France, France
  • 5 INSERM U1135 Centre d'Immunologie et de Maladies Infectieuses, Paris, Île-de-France, France
  • 6 Department of Medicine, University of Montreal, Canada; Division of Rheumatology, Centre Hospitalier de l’Université de Montréal (CHUM), Montreal, Canada
  • 7 UMR8601 Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, Paris, Île-de-France, France

The final, formatted version of the article will be published soon.

    Objective. The objective of this study was to evaluate the presence of different types of interferon in idiopathic inflammatory myopathies (IIM) and their subgroups using ultrasensitive cytokine detection techniques (SIMOA) and to assess their potential as activity biomarkers.. Disease activity was measured at the time of serum collection and assessed by manual muscle testing eight (MMT8 score 0-150), muscle enzymes to calculate the Physician Global Assessment (PGA) (0-10). Patients were classified as active if PGA>5.Serum IFN-α and IFN-γ levels was measured using the single molecule array (SIMOA) technique. Serum IFN-β level was measured by Elisa. Correlation between IFN levels and disease activity were performed.Results. We included 242 IIM patients and found a good correlation beetween type I Interferon (IFN) and dermatomyositis disease activity. IFN-α and IFN-β was highly correlated with disease activity (r=0.76 and r=0,58). To evaluate whether the different types of Interferons could serve as biomarkers of activity, we generated ROC curves.Patients with active DM had a higher median IFN-α level (0.49 pg/ml [0.1-3.7]) compared with non-active patients (0.03 pg/ml [0.01-0.07] p<0.05). The area under the curve was 0.90 IC95 (0.76-0.97) p<0.05. Furthermore, Myositis-specific antibodies appear to be associated with a different secretion profile; patients with anti-MDA 5 antibodies had higher level of IFN-α than most other antibodies (6.58 vs 0.14 p<0.005).NXP2 had higher IFN-β level than patients with Tif1γ antibodies.Serum IFN-α level measured by SIMOA is a reliable biomarker of DM activity. Myositis-specific antibodies appear to be associated with a different secretion profile. This data need to be confirmed in order to select the good therapeutics strategies in DM.

    Keywords: interferon, Dermatomyositis, immune mediated necrotizing myopathie, Anti-synthetase syndrom, inclusion body myositis, biomarker

    Received: 17 Nov 2024; Accepted: 06 Jan 2025.

    Copyright: © 2025 BOLKO, Anquetil, Llibre, Maillard, Amelin, Dorgham, BONDET, Landon-Cardinal, Toquet, Mariampillai, Malatre, Mahoudeau, HERVIER, Rodero, Gorochov, Duffy, Benveniste and ALLENBACH. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Loïs BOLKO, Rheumatology, Christian Cabrol Hospital, Reims, France

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.